Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.
Liu
Ta-Chiang
TC
1Jennerex Biotherapeutics, San Francisco, California, USA.
Hwang
Tae-Ho
TH
Bell
John C
JC
Kirn
David H
DH
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015195:Drug Design; D004345:Drug Industry / Q000379:methods; D005786:Gene Expression Regulation; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods* / Q000639:trends*; D050504:Oncolytic Viruses / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab